InnoCare Pharma Limited (HKG:9969)
11.51
-0.24 (-2.04%)
May 28, 2026, 10:20 AM HKT
InnoCare Pharma Revenue
InnoCare Pharma had revenue of 528.63M CNY in the quarter ending March 31, 2026, with 38.65% growth. This brings the company's revenue in the last twelve months to 2.52B, up 105.92% year-over-year. In the year 2025, InnoCare Pharma had annual revenue of 2.37B with 135.27% growth.
Revenue (ttm)
2.52B CNY
Revenue Growth
+105.92%
P/S Ratio
8.52
Revenue / Employee
2.14M CNY
Employees
1,176
Market Cap
24.43B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.37B | 1.37B | 135.27% |
| Dec 31, 2024 | 1.01B | 270.91M | 36.68% |
| Dec 31, 2023 | 738.54M | 113.13M | 18.09% |
| Dec 31, 2022 | 625.40M | -417.63M | -40.04% |
| Dec 31, 2021 | 1.04B | 1.04B | 76,368.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genscript Biotech | 7.47B |
| Shanghai Henlius Biotech | 7.42B |
| Zai Lab | 3.55B |
| Shanghai Junshi Biosciences | 3.10B |
| Duality Biotherapeutics | 2.06B |
| Biocytogen Pharmaceuticals (Beijing) | 1.78B |
| Keymed Biosciences | 797.12M |
| Ascentage Pharma Group International | 638.89M |
InnoCare Pharma News
- 16 hours ago - InnoCare Announces Approval of Orelabrutinib in Australia - GlobeNewsWire
- 5 days ago - 2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released - GlobeNewsWire
- 14 days ago - InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - GlobeNewsWire
- 20 days ago - InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China - GlobeNewsWire
- 21 days ago - InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China - GlobeNewsWire
- 4 weeks ago - InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE - GlobeNewsWire
- 4 weeks ago - InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability - GlobeNewsWire
- 4 weeks ago - InnoCare Pharma Quarterly report: Q1 2026 - Filings